OBJECTIVE: To compare the effect of perinatal regimens of short-course nevirapine (HIVNET 012) and zidovudine [Thai-Centers for Disease Control and Prevention (CDC) regimen] on breast milk viral shedding and perinatal transmission during the first 6 weeks postpartum in a randomized clinical trial. DESIGN: Randomized clinical trial. METHODS:Pregnant HIV-1 seropositive women in Nairobi, Kenya who planned to breastfeed were randomized to HIVNET 012 or Thai-CDC regimens. Two to four breast milk samples were collected each week between delivery and 6 weeks postpartum. Breast milkHIV-1 RNA was quantified using the Gen-Probe TMA assay. Infants were tested for HIV-1 DNA at birth and 6 weeks. RESULTS:From March to October 2003, 76 women were enrolled and 795 breast milk samples were collected from 60 women who were randomized and followed after delivery. Between 3 and 21 days postpartum, nevirapine was associated with significantly greater suppression of breast milklog10HIV-1 RNA: days 3 to 7 (1.98 versus 2.42, P = 0.1); days 8 to 14 (1.78 versus 2.48, P = 0.005); days 15 to 21 (1.90 versus 2.97, P = 0.003). At 6 weeks, the HIV-1 perinatal transmission rate was significantly lower among those who took nevirapine than zidovudine (6.8% versus 30.3%, P = 0.02). CONCLUSIONS: Compared to a peripartum zidovudine regimen, nevirapine was significantly more likely to decrease HIV-1 RNA in breast milk during the first week and through the third week postpartum following single-dose administration, and corresponded with decreased transmission risk at 6 weeks. Sustained breast milk HIV-1 suppression may contribute to the ability of nevirapine to decrease perinatal transmission of HIV-1.
RCT Entities:
OBJECTIVE: To compare the effect of perinatal regimens of short-course nevirapine (HIVNET 012) and zidovudine [Thai-Centers for Disease Control and Prevention (CDC) regimen] on breast milk viral shedding and perinatal transmission during the first 6 weeks postpartum in a randomized clinical trial. DESIGN: Randomized clinical trial. METHODS: Pregnant HIV-1 seropositive women in Nairobi, Kenya who planned to breastfeed were randomized to HIVNET 012 or Thai-CDC regimens. Two to four breast milk samples were collected each week between delivery and 6 weeks postpartum. Breast milk HIV-1 RNA was quantified using the Gen-Probe TMA assay. Infants were tested for HIV-1 DNA at birth and 6 weeks. RESULTS: From March to October 2003, 76 women were enrolled and 795 breast milk samples were collected from 60 women who were randomized and followed after delivery. Between 3 and 21 days postpartum, nevirapine was associated with significantly greater suppression of breast milk log10 HIV-1 RNA: days 3 to 7 (1.98 versus 2.42, P = 0.1); days 8 to 14 (1.78 versus 2.48, P = 0.005); days 15 to 21 (1.90 versus 2.97, P = 0.003). At 6 weeks, the HIV-1 perinatal transmission rate was significantly lower among those who took nevirapine than zidovudine (6.8% versus 30.3%, P = 0.02). CONCLUSIONS: Compared to a peripartum zidovudine regimen, nevirapine was significantly more likely to decrease HIV-1 RNA in breast milk during the first week and through the third week postpartum following single-dose administration, and corresponded with decreased transmission risk at 6 weeks. Sustained breast milk HIV-1 suppression may contribute to the ability of nevirapine to decrease perinatal transmission of HIV-1.
Authors: R Nduati; G John; D Mbori-Ngacha; B Richardson; J Overbaugh; A Mwatha; J Ndinya-Achola; J Bwayo; F E Onyango; J Hughes; J Kreiss Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: S Emery; S Bodrug; B A Richardson; C Giachetti; M A Bott; D Panteleeff; L L Jagodzinski; N L Michael; R Nduati; J Bwayo; J K Kreiss; J Overbaugh Journal: J Clin Microbiol Date: 2000-07 Impact factor: 5.948
Authors: J H Rodman; P M Flynn; B Robbins; E Jimenez; A D Bardeguez; J F Rodriguez; S Blanchard; A Fridland Journal: J Infect Dis Date: 1999-12 Impact factor: 5.226
Authors: Barbra A Richardson; Grace C John-Stewart; James P Hughes; Ruth Nduati; Dorothy Mbori-Ngacha; Julie Overbaugh; Joan K Kreiss Journal: J Infect Dis Date: 2003-02-12 Impact factor: 5.226
Authors: Valériane Leroy; John M Karon; Ahmadou Alioum; Ehounou R Ekpini; Nicolas Meda; Alan E Greenberg; Philippe Msellati; Michael Hudgens; François Dabis; Stefan Z Wiktor Journal: AIDS Date: 2002-03-08 Impact factor: 4.177
Authors: Raabya Rossenkhan; Vladimir Novitsky; Teresa K Sebunya; Jean Leidner; Jose E Hagan; Sikhulile Moyo; Laura Smeaton; Shahin Lockman; Rosemary Musonda; Thumbi Ndung'u; Simani Gaseitsiwe; Ibou Thior; Mompati Mmalane; Joseph Makhema; M Essex; Roger Shapiro Journal: AIDS Behav Date: 2012-07
Authors: Raabya Rossenkhan; Thumbi Ndung'u; Teresa K Sebunya; Jose E Hagan; Roger Shapiro; Vladimir Novitsky; Sikhulile M Moyo; Ibou Thior; Shahin Lockman; Rebecca Mitchell; Soyeon Kim; Rosemary Musonda; Erik van Widenfelt; Joseph Makhema; M Essex Journal: AIDS Res Hum Retroviruses Date: 2009-12 Impact factor: 2.205
Authors: Francis A Mmiro; Jim Aizire; Anthony K Mwatha; Susan H Eshleman; Deborah Donnell; Mary Glenn Fowler; Clemensia Nakabiito; Philippa M Musoke; J Brooks Jackson; Laura A Guay Journal: J Acquir Immune Defic Syndr Date: 2009-09-01 Impact factor: 3.731
Authors: Roger L Shapiro; Laura Smeaton; Shahin Lockman; Ibou Thior; Raabya Rossenkhan; Carolyn Wester; Lisa Stevens; Claire Moffat; Peter Arimi; Patrick Ndase; Aida Asmelash; Jean Leidner; Vladimir Novitsky; Joseph Makhema; Max Essex Journal: J Infect Dis Date: 2009-02-01 Impact factor: 5.226
Authors: Michael H Chung; James N Kiarie; Barbra A Richardson; Dara A Lehman; Julie Overbaugh; Francis Njiri; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2007-12-01 Impact factor: 3.731
Authors: Dara A Lehman; Michael H Chung; Grace C John-Stewart; Barbra A Richardson; James Kiarie; John Kinuthia; Julie Overbaugh Journal: AIDS Date: 2008-07-31 Impact factor: 4.177
Authors: Michael H Chung; James N Kiarie; Barbra A Richardson; Dara A Lehman; Julie Overbaugh; John Kinuthia; Francis Njiri; Grace C John-Stewart Journal: Antivir Ther Date: 2008